August 23, 2019 / 6:52 AM / a month ago

GSK drug boosts response rates in blood cancer patients -study

Aug 23 (Reuters) - British Drugmaker GlaxoSmithKline on Friday said its experimental cancer treatment belantamab mafodotin met the primary goal of a study for the treatment of patients with a type of blood cancer.

Two doses of the drug, also called GSK2857916, boosted response rates in adults who received prior treatment for multiple myeloma, a cancer that forms in white blood cells, GSK said, adding that it intends to submit data from the trial for regulatory filings. (Reporting by Pushkala Aripaka in Bengaluru; editing by Patrick Graham)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below